What Shilajit Does to Human Bone Cells in the Lab, and Why It Matches the Trial

In this article - Why do researchers test shilajit on bone cells? - What happened to human bone cells in the dish? - Does the trial match what the cells showed? - What do lab studies prove, and what do they not? - Common questions about shilajit and bone cells

Why do researchers test shilajit on bone cells?

A bone density scan tells you the result. It does not tell you why.

Bone is rebuilt all the time by two teams of cells. One team clears old bone and the other lays down new. After menopause, the clearing team gets louder and the building team falls behind.

RANKL is the signal that switches the clearing team on. OPG is the brake that holds it back. Estrogen keeps that brake strong, so when estrogen falls, the balance tips.

Shilajit is not a hormone. It supports the body's own estrogen signaling, and the natural next question is what it does at the cell level.

Cells in a dish answer that question cleanly. Researchers add shilajit to human bone cells and then measure the signals and the mineral they make.

Three things are worth measuring.

• Growth, meaning whether bone-forming cells multiply.
• Building, meaning whether stem cells turn into bone cells and lay down mineral.
• Signaling, meaning whether RANKL falls and OPG rises.

What happened to human bone cells in the dish?

Several independent groups have tested shilajit on bone cells since 2019. The results point the same way.

Growth of bone-forming cells

Abbasi and colleagues (J Stem Cells Regen Med, 2019) added shilajit to human osteoblast-like cells at 100 to 200 micrograms per mL. The cells grew faster than untreated cells.

Taghavi and colleagues (Adv Pharm Bull, 2020) put human stem cells on a scaffold loaded with shilajit for 48 hours. The cells multiplied faster, and the shilajit showed no toxicity to them.

Building bone

Kangari and colleagues (J Orthop Surg Res, 2022) used human stem cells taken from fat tissue. Shilajit turned them into bone-building cells, even without the usual bone-growth chemicals. Bone-building enzyme activity and calcium deposits both rose.

Pordeli and colleagues (Int J Basic Sci Med, 2025) saw the same in rat bone-marrow stem cells over 21 days, with higher enzyme activity and more calcium deposits.

The RANKL and OPG balance

Azizpour and colleagues (Sci J Kurdistan Univ Med Sci, 2020) studied human osteoblast-like cells. Shilajit lowered RANKL and raised OPG, which is the direction that holds back the clearing team.

The cells used in these studies differ, and that helps the case.

• Human osteoblast-like cells were used by Abbasi and by Azizpour.
• Human stem cells from fat tissue were used by Kangari and by Taghavi.
• Rat bone-marrow stem cells were used by Pordeli.
• Measured outcomes included growth, enzyme activity, calcium deposits and RANKL and OPG.

Does the trial match what the cells showed?

It does, and that is the interesting part. Cell work predicts a direction, and a trial in people either confirms it or it does not.

Pingali and Nutalapati published a randomized, double-blind, placebo-controlled trial in Phytomedicine in 2022, run at Nizam's Institute of Medical Sciences. It enrolled 60 postmenopausal women for 48 weeks, about 11 months. Their average hip T-score was -2.5, and they were not allowed to take calcium or vitamin D. The full design is on our clinical trial research page.

In the 500 mg group, the blood markers moved the way the cells predicted.

• OPG rose 57.3%, the brake getting stronger.
• RANKL fell 9.8%, the clearing signal getting quieter.
• CTX-1 fell 21.8%, a blood marker of bone breakdown.

Hip density finished about 4.8% above where it started on 500 mg, while the placebo group lost about 2.6%. Every single woman who took it reversed her osteoporosis.

Spine density told the same story, up about 3.8% on shilajit and down about 4.4% on placebo. The percentages were read from the paper's charts, so they are approximate.

Falling RANKL and CTX-1 alongside rising OPG and rising density is what net rebuilding looks like. Breakdown slowed and building continued.

What do lab studies prove, and what do they not?

Cell studies show a compound can act on the right machinery. They do not show what happens in a whole person, because a dish has no gut, no liver and no blood.

Some of these studies are small and some come from regional journals. The bone-cell work also tested shilajit extracts at set concentrations that are not the same as a dose taken by mouth.

That is why the trial matters. It tested shilajit in women, by mouth, for 11 months, and the signals moved in the direction the cells predicted. Zero serious adverse events were reported in that trial or in any human shilajit study.

Sixty women is a strong start and not the last word. A density trial also does not count fractures.

A fair way to hold all of this is simple.

• The cells show the how. Shilajit acts on the RANKL and OPG balance and on bone-building cells.
• The trial shows the result. Hip and spine density rose in women who took it.
• The gap that remains is fracture outcomes, which only longer trials can measure.

More of the library, including the animal and mineral studies, sits on our shilajit bone research page.

Optimum Shilajit

Optimum Shilajit is purified resin from the Altai mountains, third-party tested for heavy metals with results published. Two tablets with breakfast, made in small batches by a family-owned company out of Florida, with a 90-day money-back guarantee.

See Optimum Shilajit